Ognomy Inc., a trailblazing telemedicine platform dedicated to transforming sleep apnea care, proudly announces the successful completion of its Series Seed Preferred financing round, bringing its total funding to over $6.8 million. This funding milestone coincides with the company surpassing 11,000 patients served, marking a pivotal moment in its mission to make high-quality sleep care accessible to all. The financing round was led by Impellent Ventures, with significant support from a strategic partner in the sleep medicine industry, underscoring the growing confidence in Ognomy’s innovative approach.
Ognomy’s platform enables patients to connect with clinicians within days and start personalized treatment plans from the comfort of their own homes. Currently, the company has coverage in 43 states and aims to achieve full nationwide coverage by the end of 2024. Ognomy is tackling the staggering statistic that over 80% of individuals with sleep apnea remain undiagnosed and untreated, providing a vital solution that improves sleep, reduces chronic disease risk, and enhances overall health.
What You Need to Know:
- Significant Funding Achievement: Ognomy has raised over $6.8 million in its Series Seed Preferred round, led by Impellent Ventures, reflecting strong investor confidence in its mission to revolutionize sleep apnea care. This funding will accelerate Ognomy’s growth and innovation.
- Nationwide Expansion Plans: With coverage in 43 states and a goal to reach full nationwide coverage by the end of 2024, Ognomy is expanding its reach to ensure that accessible, high-quality sleep apnea care is available to everyone in need.
- AI-Driven Innovation: The newly raised funds will be used to integrate advanced AI-driven automation and information exchange into Ognomy’s platform, streamlining the patient journey from diagnosis to treatment and ongoing management, making the process faster, more efficient, and more accessible.
“We are thrilled to have the support of Impellent Ventures and our new strategic partner,” said Dr. Daniel Rifkin, CEO of Ognomy. “This funding will allow us to accelerate our mission of providing accessible, high-quality care for sleep apnea patients across the country. With AI-driven automation and a fully integrated platform, we are poised to revolutionize the way sleep apnea is diagnosed and treated.”
For more information about Ognomy Inc.’s nationwide mission to improve sleep health, please visit http://www.ognomy.com.
